Guidelines

Impact on Patient Care: The 2016 European Heart Failure Guidelines

In this issue of European Cardiology Review, Professor Bayes Genis and team give a clear and robust review of the 2016 European Society of Cardiology guidelines for the diagnosis and treatment of acute and chronic heart failure (HF).1 The guidelines were last updated in 2012 and combined for the first time chronic and acute care.

Applying Heart Failure Management to Improve Health Outcomes: But WHICH One?

Primarily due to significant treatment advancements to prevent previously fatal acute cardiac events, the burden of heart failure (HF), characterised by chronic symptoms, acute hospitalisations and premature mortality, continues to rise.1,2 Latest expert guidelines3,4 confirmed by meta-analyses5,6 support the application of multidisciplinary HF management programs to improve health outcomes.

Quality of Physician Adherence to Guideline Recommendations for Life-saving Treatment in Heart Failure: an International Survey

Advances in diagnosis and treatment have improved the outlook for the estimated 26 million patients with heart failure (HF) worldwide,1 but there remains a continuing need for further reduction in mortality and hospitalisation and the associated social and financial consequences of the disease.

The Role of Ivabradine and Trimetazidine in the New ESC HF Guidelines

Chronic heart failure (HF), a complex and heterogeneous clinical syndrome, is a major cause of morbidity and mortality worldwide, and represents a major challenge to health care systems. The prevalence of HF and the number of hospitalisations is rising, even more in the ageing population.1 The direct costs of HF management reached 1–2 % of total health care expenditure and approximately two-thirds are attributable to hospitalisations.

Promising New Therapies in Heart Failure: Ivabradine and the Neprilysin Inhibitors

Decades ago heart failure (HF) was primarily regarded as a hemodynamic disorder in an attempt to explain patients’ symptoms and disability. This hemodynamic model led to the widespread evaluation of peripheral vasodilators (to increase cardiac output by decreasing systemic vascular resistance against the failing heart). It also led to the development of novel positive inotropic agents (to directly increase cardiac output). Long-term use of these drugs failed to improve symptoms and was frequently accompanied by an increase in the risk of death.